Resverlogix Corp. (RVXCF)

[growacet]

Haven't been watching this forum much....

The most active forum for RVX that I've found is agora....

With BETonMACE being an events based trial I don't really think it matters when the futility analysis is triggered....whether its mid or late 2017 or early 2018. The only thing that matters imo is that the half way results show that Apabetalone leads to a statistically significant Relative Risk Reduction (RRR) of Major Adverse Cardiac Events (MACE).

Rather than focus on PPS I think its better to consider the potential Market Capitalization, which right now sits around $210 million CDN or $165 million USD. With a positive futility analysis I don't think a $1 billion USD MC is unreasonable, and a completed and successful trial....maybe $5 billion.

If Apabetalone is successful is achieving a significant RRR in patients with Diabetes Mellitus (fancy way of saying full blown insulin dependent diabetes) then I think that bodes well for other indications like Chronic Kidney Disease, Thrombosis and other orphan indications and possibly even Alzeheimers as that disease is said to be impacted by high cholesterol levels.

FDA approval of the BETonMACE trial would also be a big plus, right now its approved by the European regulatory body, but not the FDA. The company is reportedly working on FDA approval, that too could give a bump.

There are a lot of potential catalysts here that could send the PPS significantly higher imo....but of course the key word there is potential, nothing is a sure thing.